Compare COCO & SRPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | COCO | SRPT |
|---|---|---|
| Founded | 2004 | 1980 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Beverages (Production/Distribution) | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 2.5B |
| IPO Year | 2021 | 2000 |
| Metric | COCO | SRPT |
|---|---|---|
| Price | $76.29 | $16.59 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 9 | 29 |
| Target Price | ★ $57.75 | $25.85 |
| AVG Volume (30 Days) | 1.6M | ★ 2.6M |
| Earning Date | 04-29-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 26.60 | N/A |
| EPS | 0.50 | ★ 2.88 |
| Revenue | N/A | ★ $2,198,237,000.00 |
| Revenue This Year | $16.12 | N/A |
| Revenue Next Year | $11.40 | N/A |
| P/E Ratio | $151.99 | ★ $5.85 |
| Revenue Growth | N/A | ★ 15.58 |
| 52 Week Low | $31.82 | $10.42 |
| 52 Week High | $79.99 | $43.92 |
| Indicator | COCO | SRPT |
|---|---|---|
| Relative Strength Index (RSI) | 67.16 | 32.33 |
| Support Level | $50.99 | $15.70 |
| Resistance Level | $79.99 | $19.62 |
| Average True Range (ATR) | 2.73 | 1.01 |
| MACD | -0.16 | -0.35 |
| Stochastic Oscillator | 68.57 | 1.51 |
The Vita Coco Co Inc is a plant-based functional hydration platform. Its products include Vita Coco Coconut Water, Private Label including coconut water and oil, and Other including Runa, Ever & Ever, and PWR LIFT product offerings, Vita Coco product extensions beyond coconut water, such as Vita Coco Sparkling, coconut milk products, and others. The company has two segments: The Americas segment which comprises of operations in the U.S. and Canada; and The International segment that comprises of operations in Europe, the Middle East, Africa and the Asia Pacific regions. The Americas segment derives maximum revenue. Geographical presence of the company is in United States, United Kingdom and All other countries.
Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.